The Latest Cardiac and Vascular News
Bridge Occlusion Balloon Catheter Model 590-001 by Spectranetics: Class I Recall – Risk of Blocked Guidewire Lumen Preventing Balloon Utilization ISSUE: Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in some device units. If a device with a blocked guidewire lumen […]
AMSTERDAM and LAS VEGAS, Sept. 14, 2017 /PRNewswire/ — Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating the efficacy of Philips Spectranetics’ Stellarex .035″ drug-coated balloon (DCB) for peripheral arterial disease (PAD) in comparison to uncoated balloon angioplasty. Marianne […]
Philips subsidiary Spectranetics recalls Bridge occlusion balloon AUGUST 31, 2017 BY BRAD PERRIELLO , MassDevice Royal Philips (NYSE:PHG) subsidiary Spectranetics recalled its Bridge occlusion balloon after receiving reports of blocked guidewire lumens. The Bridge device is used to temporarily block the superior vena cava for emergency control of hemorrhage. Spectranetics said the August 25 recall was […]
COLORADO SPRINGS, Colo., Aug. 10, 2017 (GLOBE NEWSWIRE) — The Spectranetics Corporation (NASDAQ:SPNC) (“the Company”), a developer and manufacturer of single-use medical devices used in minimally invasive procedures within the cardiovascular system, today announced the occurrence of a Fundamental Change, Make-Whole Adjustment Event and Share Exchange Event, and the execution […]
Amsterdam, the Netherlands and Colorado Springs, CO, U.S. – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has completed the acquisition of The Spectranetics Corporation (NASDAQ: SPNC), a U.S.-based global leader in vascular intervention and lead management solutions. Spectranetics’ financial results will be consolidated as part of […]
COLORADO SPRINGS, Colo., July 26, 2017 (GLOBE NEWSWIRE) — The Spectranetics Corporation (NASDAQ:SPNC) today announced receipt of U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) of the Stellarex™ drug-coated balloon (DCB), designed to restore and maintain blood flow to the superficial femoral and popliteal arteries in patients with peripheral arterial disease […]
COLORADO SPRINGS, Colo., July 13, 2017 (GLOBE NEWSWIRE) — The Spectranetics Corporation (NASDAQ:SPNC) (“the Company”) today announced that it will release financial results for the second quarter ended June 30, 2017, after market close on August 3, 2017. Due to the pending transaction with Royal Philips, the Company will not hold an […]
6/28/2017 5:53:44 AM Philips To Acquire The Spectranetics Corporation To Accelerate Expansion In Image-Guided Therapy Devices To Treat Cardiac And Peripheral Vascular Disease AMSTERDAM, the Netherlands and COLORADO SPRINGS, Colo., June 28, 2017 (GLOBE NEWSWIRE) — Royal Philips(NYSE:PHG) (AEX:PHIA), a global leader in health technology, and The Spectranetics Corporation (NASDAQ:SPNC), a U.S.-based global […]
